ApoB100/LDLR-/- Hypercholesterolaemic Mice as a Model for Mild Cognitive Impairment and Neuronal Damage

Recent clinical findings support the notion that the progressive deterioration of cholesterol homeostasis is a central player in Alzheimer's disease (AD). Epidemiological studies suggest that high midlife plasma total cholesterol levels are associated with an increased risk of AD. This paper reports the plasma cholesterol concentrations, cognitive performance, locomotor activity and neuropathological signs in a murine model (transgenic mice expressing apoB100 but knockout for the LDL receptor [LDLR]) of human familial hypercholesterolaemia (FH). From birth, these animals have markedly elevated LDL-cholesterol and apolipoprotein B100 (apoB100) levels. These transgenic mice were confirmed to have higher plasma cholesterol concentrations than wild-type mice, an effect potentiated by aging. Further, 3-month-old transgenic mice showed cholesterol (total and fractions) concentrations considerably higher than those of 18-month-old wild-type mice. The hypercholesterolaemia of the transgenic mice was associated with a clear locomotor deficit (as determined by rotarod, grip strength and open field testing) and impairment of the episodic-like memory (determined by the integrated memory test). This decline in locomotor activity and cognitive status was associated with neuritic dystrophy and/or the disorganization of the neuronal microtubule network, plus an increase in astrogliosis and lipid peroxidation in the brain regions associated with AD, such as the motor and lateral entorhinal cortex, the amygdaloid basal nucleus, and the hippocampus. Aortic atherosclerotic lesions were positively correlated with age, although potentiated by the transgenic genotype, while cerebral β-amyloidosis was positively correlated with genetic background rather than with age. These findings confirm hypercholesterolaemia as a key biomarker for monitoring mild cognitive impairment, and shows these transgenic mice can be used as a model for cognitive and psycho-motor decline.

[1]  L. Thal,et al.  Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology , 2003, Neurology.

[2]  Prasanthi,et al.  Molecular Neurodegeneration Differential Effects of 24-hydroxycholesterol and 27-hydroxycholesterol on Β-amyloid Precursor Protein Levels and Processing in Human Neuroblastoma Sh-sy5y Cells , 2022 .

[3]  Patrick R Hof,et al.  Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. , 2010, The Mount Sinai journal of medicine, New York.

[4]  Stephen G. Young,et al.  A mouse model of human familial hypercholesterolemia: Markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet , 1998, Nature Medicine.

[5]  M. Schrag,et al.  Deposition of iron and β‐amyloid plaques is associated with cortical cellular damage in rabbits fed with long‐term cholesterol‐enriched diets , 2006, Journal of neurochemistry.

[6]  J. Poirier.  Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. , 2003, Trends in molecular medicine.

[7]  Rodrigo Alonso,et al.  Higher incidence of mild cognitive impairment in familial hypercholesterolemia. , 2010, The American journal of medicine.

[8]  M. Hayden,et al.  Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer’s disease mouse models with abundant Aβ in plasma , 2006, Neurobiology of Disease.

[9]  R. Kalaria,et al.  The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. , 1990, The American journal of pathology.

[10]  T. Edano,et al.  A method of direct measurement for the enzymatic determination of cholesteryl esters Published, JLR Papers in Press, October 16, 2003. DOI 10.1194/jlr.D300024-JLR200 , 2004, Journal of Lipid Research.

[11]  K. Fukuchi,et al.  Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice , 2006, Neurobiology of Aging.

[12]  R. Nitrini,et al.  Increased apolipoprotein B serum concentration in Alzheimer's disease , 1999, Acta neurologica Scandinavica.

[13]  J. Burgos,et al.  Simvastatin is the statin that most efficiently protects against kainate-induced excitotoxicity and memory impairment. , 2011, Journal of Alzheimer's disease : JAD.

[14]  A. Blokland,et al.  Low-density lipoprotein receptor-knockout mice display impaired spatial memory associated with a decreased synaptic density in the hippocampus , 2004, Neurobiology of Disease.

[15]  H. Feldman,et al.  Cholesterol in Alzheimer's disease , 2005, The Lancet Neurology.

[16]  Robert Lalonde,et al.  Relations between open-field, elevated plus-maze, and emergence tests as displayed by C57/BL6J and BALB/c mice , 2008, Journal of Neuroscience Methods.

[17]  W. Schneider,et al.  From cholesterol transport to signal transduction: low density lipoprotein receptor, very low density lipoprotein receptor, and apolipoprotein E receptor-2. , 2000, Biochimica et biophysica acta.

[18]  W. Klein,et al.  Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. , 1996, The Journal of biological chemistry.

[19]  G. Cole,et al.  Lipoprotein effects on aβ accumulation and degradation by microglia in vitro , 1999, Journal of neuroscience research.

[20]  K Yaffe,et al.  Midlife cardiovascular risk factors and risk of dementia in late life , 2005, Neurology.

[21]  R. Mayeux,et al.  Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. , 2010, Archives of neurology.

[22]  M. Emmerling,et al.  Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. , 1998, Biochemical and biophysical research communications.

[23]  E. Cankurtaran,et al.  Are serum lipid and lipoprotein levels related to dementia? , 2005, Archives of gerontology and geriatrics.

[24]  Stephen W. Scheff,et al.  Induction of Alzheimer-like β-Amyloid Immunoreactivity in the Brains of Rabbits with Dietary Cholesterol , 1994, Experimental Neurology.

[25]  R. Hammer,et al.  Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.

[26]  Joseph P. Huston,et al.  Integrated memory for objects, places, and temporal order: Evidence for episodic-like memory in mice , 2005, Neurobiology of Learning and Memory.

[27]  D. Sparks,et al.  Is there a characteristic lipid profile in Alzheimer's disease? , 2005, Journal of Alzheimer's disease : JAD.

[28]  G. Winocur,et al.  Cognitive impairment in rats fed high-fat diets: a specific effect of saturated fatty-acid intake. , 1996, Behavioral neuroscience.

[29]  H. Scheich,et al.  Overexpression of human apolipoprotein B-100 induces severe neurodegeneration in transgenic mice. , 2008, Journal of proteome research.

[30]  K. Fukuchi,et al.  Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. , 2003, The American journal of pathology.

[31]  A. Hofman,et al.  Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study , 1997, The Lancet.

[32]  S. Frautschy,et al.  Low density lipoprotein receptor-related proteins (LRPs), Alzheimer's and cognition. , 2005, Current drug targets. CNS and neurological disorders.

[33]  K. Jellinger,et al.  The enigma of vascular cognitive disorder and vascular dementia , 2007, Acta Neuropathologica.

[34]  David A. Bennett,et al.  Genetic association of low density lipoprotein receptor and Alzheimer's disease , 2005, Neurobiology of Aging.

[35]  H. Bimonte-Nelson,et al.  High cholesterol‐induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice , 2008, Journal of neurochemistry.

[36]  J. Leverenz,et al.  Diet-induced hypercholesterolemia enhances brain A&bgr; accumulation in transgenic mice , 2002, Neuroreport.

[37]  D. Bennett,et al.  Grip Strength and the Risk of Incident Alzheimer’s Disease , 2007, Neuroepidemiology.

[38]  W. Klein,et al.  Cholesterol Modulates -Secretase Cleavage of Amyloid Precursor Protein (*) , 1996, The Journal of Biological Chemistry.

[39]  W. Aronow,et al.  Association of abnormal serum lipids in elderly persons with atherosclerotic vascular disease and dementia, atherosclerotic vascular disease without dementia, dementia without atherosclerotic vascular disease, and no dementia or atherosclerotic vascular disease. , 2003, The journals of gerontology. Series A, Biological sciences and medical sciences.

[40]  Rong Wang,et al.  Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model , 2000, Neurobiology of Disease.

[41]  C. Brayne,et al.  Highlights of Papers in Clinical Investigations Section: Vascular Risk and Cognitive Impairment in an Older, British, African‐Caribbean Population , 2001, Journal of the American Geriatrics Society.

[42]  I. Ferrer,et al.  Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease , 2004, Brain pathology.

[43]  L. Thal,et al.  Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease , 1996, Neurology.

[44]  W. Walz,et al.  Immunocytochemical evidence for a distinct GFAP-negative subpopulation of astrocytes in the adult rat hippocampus , 1998, Neuroscience Letters.

[45]  J. Poirier,et al.  APOE and cholesterol homeostasis in Alzheimer's disease. , 2010, Trends in molecular medicine.

[46]  F. Civeira,et al.  Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. , 2004, Atherosclerosis.

[47]  D. Price,et al.  Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. , 1987, Science.

[48]  C. Duyckaerts,et al.  Alzheimer disease models and human neuropathology: similarities and differences , 2007, Acta Neuropathologica.

[49]  Amaia M. Arranz,et al.  Neuroprotection by two polyphenols following excitotoxicity and experimental ischemia , 2006, Neurobiology of Disease.

[50]  M. M. Mielke,et al.  High total cholesterol levels in late life associated with a reduced risk of dementia , 2005, Neurology.

[51]  J. D. Smith,et al.  Mouse models of atherosclerosis. , 1998, Laboratory animal science.

[52]  J. Toutain,et al.  Sensorimotor and cognitive deficits after transient middle cerebral artery occlusion in the mouse , 2007, Experimental Neurology.

[53]  S. Toyokuni,et al.  The monoclonal antibody specific for the 4‐hydroxy‐2‐nonenal histidine adduct , 1995, FEBS letters.

[54]  J. Łuszczki,et al.  Characterization of acute adverse-effect profiles of selected antiepileptic drugs in the grip-strength test in mice , 2009, Pharmacological reports : PR.